LNP-delivered CRISPR gene editing is trapped in the liver: current lipid nanoparticle formulations cannot efficiently target non-hepatic tissues, blocking therapies for most genetic diseases

Developers of in vivo CRISPR-Cas9 gene therapies -- including Intellia Therapeutics, Verve Therapeutics, and academic groups -- face a fundamental delivery limitation: lipid nanoparticles (LNPs), the most clinically advanced non-viral delivery vehicle, accumulate overwhelmingly in the liver due to apolipoprotein E adsorption, making it extremely difficult to achieve therapeutic gene editing in the lungs, brain, muscle, heart, or other tissues where most genetic diseases manifest. Why it matters: the liver tropism of standard LNPs means that only liver-expressed genetic diseases (such as transthyretin amyloidosis or hereditary angioedema) are currently addressable with LNP-CRISPR, so the vast majority of the ~7,000 known rare genetic diseases affecting non-hepatic tissues remain out of reach for this otherwise transformative technology, so companies pursuing non-liver targets must use AAV viral vectors with their own manufacturing and immunogenicity limitations, so the promise of one-time curative gene editing remains unfulfilled for diseases like Duchenne muscular dystrophy, cystic fibrosis, and sickle cell disease (where ex vivo editing requires toxic myeloablative conditioning), so billions in gene therapy R&D investment cannot translate to clinical impact for most patients. The structural root cause is that LNP biodistribution is governed by endogenous lipoprotein biology that directs particles to hepatocytes, and while recent research (adding cationic lipids for lung targeting, anionic lipids for spleen targeting) shows promise, these formulations have not yet been validated in human clinical trials -- the field lacks a generalizable, modular targeting platform equivalent to what antibody-drug conjugates achieved for oncology.